Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ublituximab + Ibrutinib vs Ibrutinib in High-Risk CLL
NCT02301156Phase 3Completed
- Sponsor
- TG Therapeutics, Inc.
- Start
- Jan 2015
- Primary completion
- Apr 2020
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
A Phase 3 trial of ublituximab in chronic lymphocytic leukemia (CLL), sponsored by TG Therapeutics, Inc.. Started Jan 2015; status: completed.
02
Drugs
ublituximab
03
Conditions
chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT02301156.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02301156.